Regeneron Stays Strong Despite Rival Drug, Buoyed by Pipeline Progress and Dupixent Sales
-
Regeneron's drug Eylea faces competition from Roche's Vabysmo, but new high-dose Eylea may help it regain market share.
-
Regeneron's revenue grew 11% last quarter thanks to eczema drug Dupixent's sales growth.
-
Regeneron is expanding pipeline through collaborations like with Intellia on gene editing therapies.
-
Regeneron acquired Decibel Therapeutics and its hearing loss gene therapies for $109M.
-
With pipeline progress, Dupixent growth potential, and new Eylea formulation, Regeneron remains a solid investment.